ZABEL, Markus, Simon SCHLOGL, Andrzej LUBINSKI, Jesper Hastrup SVENDSEN, Axel BAUER, Elena ARBELO, Sandro BRUSICH, David CONEN, Iwona CYGANKIEWICZ, Michael DOMMASCH, Panagiota FLEVARI, Jan GALUSZKA, Jim HANSEN, Gerd HASENFUSS, Robert HATALA, Heikki V. HUIKURI, Tuomas KENTTA, Tomasz KUCEJKO, Helge HAARMANN, Markus HARDEN, Svetoslav IOVEV, Stefan KAAB, Gabriela KALISKA, Andreas KATSIMARDOS, Jaroslaw D. KASPRZAK, Dariusz QAVOQ, Lars LUTHJE, Marek MALIK, Tomáš NOVOTNÝ, Nikola PAVLOVIC, Peter PERGE, Christian ROVER, Georg SCHMIDT, Tchavdar SHALGANOV, Rajeeva SRITHARAN, Martin SVETLOSAK, Zoltan SALLO, Janko SZAVITS-NOSSAN, Vassil TRAYKOV, Bert VANDENBERK, Vasil VELCHEV, Marc A. VOS, Stefan N. WILLICH, Tim FRIEDE, Rik WILLEMS, Bela MERKELY and Christian STICHERLING. Present criteria for prophylactic ICD implantation: Insights from the EU-CERT-ICD (Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in EUrope) project. Journal of Electrocardiology. Philadelphia: Churchill Livingstone, 2019, vol. 57, NOV-DEC 201, p. "S34"-"S39", 6 pp. ISSN 0022-0736. Available from: https://dx.doi.org/10.1016/j.jelectrocard.2019.09.001.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Present criteria for prophylactic ICD implantation: Insights from the EU-CERT-ICD (Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in EUrope) project
Authors ZABEL, Markus (276 Germany, guarantor), Simon SCHLOGL (276 Germany), Andrzej LUBINSKI (616 Poland), Jesper Hastrup SVENDSEN (208 Denmark), Axel BAUER (276 Germany), Elena ARBELO (724 Spain), Sandro BRUSICH (191 Croatia), David CONEN (756 Switzerland), Iwona CYGANKIEWICZ (616 Poland), Michael DOMMASCH (276 Germany), Panagiota FLEVARI (300 Greece), Jan GALUSZKA (203 Czech Republic), Jim HANSEN (191 Croatia), Gerd HASENFUSS (276 Germany), Robert HATALA (300 Greece), Heikki V. HUIKURI (246 Finland), Tuomas KENTTA (246 Finland), Tomasz KUCEJKO (616 Poland), Helge HAARMANN (276 Germany), Markus HARDEN (276 Germany), Svetoslav IOVEV (100 Bulgaria), Stefan KAAB (208 Denmark), Gabriela KALISKA (703 Slovakia), Andreas KATSIMARDOS (300 Greece), Jaroslaw D. KASPRZAK (616 Poland), Dariusz QAVOQ (616 Poland), Lars LUTHJE (276 Germany), Marek MALIK (826 United Kingdom of Great Britain and Northern Ireland), Tomáš NOVOTNÝ (203 Czech Republic, belonging to the institution), Nikola PAVLOVIC (276 Germany), Peter PERGE (276 Germany), Christian ROVER (276 Germany), Georg SCHMIDT (276 Germany), Tchavdar SHALGANOV (276 Germany), Rajeeva SRITHARAN (484 Mexico), Martin SVETLOSAK (703 Slovakia), Zoltan SALLO (276 Germany), Janko SZAVITS-NOSSAN (276 Germany), Vassil TRAYKOV (276 Germany), Bert VANDENBERK (276 Germany), Vasil VELCHEV (276 Germany), Marc A. VOS (276 Germany), Stefan N. WILLICH (276 Germany), Tim FRIEDE (276 Germany), Rik WILLEMS (276 Germany), Bela MERKELY (276 Germany) and Christian STICHERLING (756 Switzerland).
Edition Journal of Electrocardiology, Philadelphia, Churchill Livingstone, 2019, 0022-0736.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 0.944
RIV identification code RIV/00216224:14110/19:00112413
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.jelectrocard.2019.09.001
UT WoS 000503909200007
Keywords in English Implantable cardioverter defibrillator; Risk factors; Mortality; Sudden cardiac death
Tags 14110211, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 15/1/2020 15:29.
Abstract
Background: The clinical effectiveness of primary prevention implantable cardioverter defibrillator (ICD) therapy is under debate. It is urgently needed to better identify patients who benefit from prophylactic ICD therapy. The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators (EU-CERT-ICD) completed in 2019 will assess this issue. Summary: The EU-CERT-ICD is a prospective investigator-initiated non-randomized, controlled, multicenter observational cohort study done in 44 centers across 15 European countries. A total of 2327 patients with heart failure due to ischemic heart disease or dilated cardiomyopathy indicated for primary prophylactic ICD implantation were recruited between 2014 and 2018 (>1500 patients at first ICD implantation, >750 patients non-randomized non-ICD control group). The primary endpoint was all-cause mortality, and first appropriate shock was co-primary endpoint. At baseline, all patients underwent 12-lead ECG and Holter-ECG analysis using multiple advanced methods for risk stratification as well as documentation of clinical characteristics and laboratory values. The EU-CERT-ICD data will provide much needed information on the survival benefit of preventive ICD therapy and expand on previous prospective risk stratification studies which showed very good applicability of clinical parameters and advanced risk stratifiers in order to define patient subgroups with above or below average ICD benefit. Conclusion: The EU-CERT-ICD study will provide new and current data about effectiveness of primary prophylactic ICD implantation. The study also aims for improved risk stratification and patient selection using clinical risk markers in general, and advanced ECG risk markers in particular. (C) 2019 Elsevier Inc. All rights reserved.
PrintDisplayed: 20/7/2024 12:12